Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
ICCM Transcript
IceCure Medical Ltd (ICCM) Q1 2026 Earnings Call Transcript
Positive5-12
The earnings call summary reveals a positive sentiment with strong revenue growth (25% YoY), improved gross margins, and reduced net loss. The company's strategic focus on breast cancer treatment and operational highlights indicate promising prospects. However, regulatory hurdles and competitive pressures present risks. Overall, the financial performance and strategic initiatives suggest a positive outlook for the stock price, likely to increase by 2% to 8% over the next two weeks.
IceCure Medical Ltd (ICCM) Q4 2025 Earnings Call Transcript
Positive3-17
The earnings call summary presents a positive outlook with record revenue, FDA marketing authorization, and strategic growth plans. The Q&A section highlights the company's efforts to improve reimbursement and expand into new markets, with some uncertainty in timelines. Despite challenges in scaling and market penetration, the strong financial performance and optimistic guidance suggest a positive stock price movement.
IceCure Medical Ltd (ICCM) Q3 2025 Earnings Call Transcript
Unknown11-19
The company's financial performance shows declining revenue, gross profit, and margins, indicating challenges in maintaining profitability. Despite the optimism around FDA approval and market potential, the lack of a concrete timeline for regulatory approvals and the unclear management responses in the Q&A create uncertainty. The ongoing net losses and limited cash position add to financial strain. These factors, combined with supply chain and sales variability, suggest a negative market reaction, likely in the -2% to -8% range, especially given the lack of market cap information for a more precise prediction.
IceCure Medical Ltd (ICCM) Q2 2025 Earnings Call Transcript
Unknown8-13
The earnings call reveals several concerns: declining revenue and gross margin, increased net loss, and dependency on FDA approval for U.S. market growth. The Q&A highlighted uncertainties around the post-market study budget and lack of specific sales projections for Europe and Japan. While there is interest in ProSense and potential reimbursement, the financial metrics and market adoption risks overshadow these positives, suggesting a negative sentiment.
ICCM Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
